Oryzon gets EMA approval to start phase II Hope-2 vafidemstat study for PMS treatment
The study is for Phelan–McDermid syndrome treatment. Reuters source text says the approval is to initiate the Hope-2 phase II study.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Oryzon Gets EMA Approval To Start Phase II Study Of Vafidemstat For PMS Treatment
Oryzon Genomics SA BME:ORY